Shorla Oncology Announces FDA Filing Acceptance of New Drug ...
Shorla Oncology announced FDA acceptance of its NDA for SH-201, a palatable oral liquid to treat certain leukemias and cancers, with a PDUFA action date of November 30, 2024. SH-201 aims to provide an alternative treatment for patients lacking oral liquid options, marking a significant step for the company and those affected by these diseases.
Reference News
Shorla Oncology Announces FDA Filing Acceptance of New Drug ...
Shorla Oncology announced FDA acceptance of its NDA for SH-201, a palatable oral liquid to treat certain leukemias and cancers, with a PDUFA action date of November 30, 2024. SH-201 aims to provide an alternative treatment for patients lacking oral liquid options, marking a significant step for the company and those affected by these diseases.